These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 12171721

  • 1. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G.
    Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G.
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [Abstract] [Full Text] [Related]

  • 3. Friends, faithfulness and fortunes.
    Hale G.
    Cytotherapy; 2001; 3(3):135-6. PubMed ID: 12171720
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alemtuzumab in stem cell transplantation.
    Hale G.
    Med Oncol; 2002; 19 Suppl():S33-47. PubMed ID: 12180491
    [Abstract] [Full Text] [Related]

  • 7. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
    Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S.
    Blood; 2010 Oct 21; 116(16):3080-8. PubMed ID: 20587785
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K, Wilson WH.
    Leuk Lymphoma; 2010 Sep 21; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract] [Full Text] [Related]

  • 10. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation.
    Novitzky N, Rouskova A.
    Cytotherapy; 2001 Sep 21; 3(3):165-73. PubMed ID: 12171723
    [Abstract] [Full Text] [Related]

  • 11. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ, Clarke E, Blair A, Evely R, Hale G, Waldmann H, Brookes S, Pamphilon DH.
    Cytotherapy; 2000 Sep 21; 2(1):5-14. PubMed ID: 12042050
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH.
    Cytotherapy; 2001 Sep 21; 3(3):203-10. PubMed ID: 12171727
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.